Aziz Sawaf
Chief Financial Officer
Replay available
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call
Theravance Biopharma, Inc. (NASDAQ: TBPH) Q3 2025 earnings conference call, held 2025-11-10. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Rick Winningham
Chief Executive Officer
Anya Miller
Head of Development
Rhonda Farnham
Chief Business Officer
Ellen Horst
Analyst, TD Cowen
Julian Harrison
Analyst, BTIG
Douglas Howe
Analyst, HC Wainwright
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Theravance Biopharma, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.339 Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the TheraVance 00:00:04.339 -- 00:00:08.266 Biopharma third quarter 2025 conference call. 00:00:08.266 -- 00:00:11.932 During the presentation, all participants will be in a listen-only mode. 00:00:11.932 -- 00:00:15.659 A question and answer session will follow the company's formal remarks. 00:00:15.659 -- 00:00:19.606 To ask a question, press star 11 on your telephone. 00:00:19.606 -- 00:00:24.813 If listening via webcast, please mute audio on your webcast device before 00:00:24.813 -- 00:00:29.920 asking a question over the phone. I will repeat these instructions after management completes 00:00:29.920 -- 00:00:34.066 their prepared remarks. Also, today's conference call is being recorded. 00:00:34.066 -- 00:00:38.913 And now I'd like to turn the call over to Rick Winningham, Chief Executive Officer. 00:00:38.913 -- 00:00:41.434 Please go ahead, sir. 00:00:42.057 -- 00:00:47.785 Good afternoon, and welcome to Theravance Biopharma's third quarter 2025 earnings 00:00:47.785 -- 00:00:53.072 results conference call. On slide two, you'll find our forward-looking statements 00:00:53.072 -- 00:00:58.199 disclaimer, which covers certain risk factors which could cause actual results to differ 00:00:58.199 -- 00:01:03.326 materially from any forward-looking statements we might make in today's call 00:01:03.326 -- 00:01:07.772 and which are described further in our filings with the SEC. 00:01:07.772 -- 00:01:13.179 Moving to slide three, I'm joined today by Rhonda Farnham, Chief Business Officer, 00:01:13.179 -- 00:01:18.787 Anya Miller, Head of Development, and Aziz Sawaf, Chief Financial Officer. 00:01:18.787 -- 00:01:21.550 Turning to slide four, TheraVance 00:01:21.5...